Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Lymphoblastic LymphomaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT06533748
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
- Conditions
- Multiple MyelomaHematopoietic Stem Cell Mobilization
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- The Affiliated People's Hospital of Ningbo University
- Target Recruit Count
- 99
- Registration Number
- NCT06520176
- Locations
- 🇨🇳
Dongyang People's Hospital, Dongyang, Zhejiang, China
🇨🇳The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳The First Hospital of Jiaxing, Jiaxing, Zhejiang, China
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
- Conditions
- Non-Hodgkin's LymphomaHematopoietic Stem Cell Mobilization
- Interventions
- Combination Product: CHOPCombination Product: Hyper-CVADCombination Product: ID-MTX + Ara-CCombination Product: DA-EPOCHCombination Product: GDPCombination Product: GDPECombination Product: ICECombination Product: DICE
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- The Affiliated People's Hospital of Ningbo University
- Target Recruit Count
- 99
- Registration Number
- NCT06520163
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Lishui Central Hospital, Lishui, Zhejiang, China
🇨🇳Dongyang People's Hospital, Dongyang, Zhejiang, China
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 39
- Registration Number
- NCT06504199
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
🇨🇳Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Venetoclax in Combination with Cladribine and Cytarabine Alternating with Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
- Conditions
- Acute Myeloid LeukemiaAcute Monocytic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: EchocardiographyProcedure: Lumbar PunctureProcedure: Multigated Acquisition ScanOther: Questionnaire Administration
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06504459
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 47
- Registration Number
- NCT06497062
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
- Conditions
- Relapsed/Refractory Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Target Recruit Count
- 89
- Registration Number
- NCT06489808
- Locations
- 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating with Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
- Conditions
- Refractory Acute LeukemiaRelapsed Acute Leukemia
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06474663
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Anthracyclines or anthraquinones
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT06451861
- Locations
- 🇨🇳
Foshan First People's Hospital, Foshan, Guangdong, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML
- Conditions
- Relapsed/Refractory Acute Myeloid LeukaemiaMyeloid Malignancy
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 34
- Registration Number
- NCT06434662
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.